Xiao Hong Chen (Wei Chen)

Years Active: 2020-2021
Publications (10 Years): 2

U.S. Food and Drug Administration

University of Massachusetts Amherst (PHD)

This page only lists publications with an associated author ORCID identifier.

Affiliation History

U.S. Food and Drug Administration May 10 1998

United States

Quality Assessment Lead :: CDER

Education History

University of Massachusetts Amherst Sep 01 1989 - May 10 2004

United States

PHD :: Biochemistry and Molecular Biology

Publications

Elaine Chang, Chana Weinstock, Lijun Zhang, Mallorie H Fiero, Miao Zhao, Eias Zahalka, Tiffany K Ricks, Jeanne Fourie Zirkelbach, Junshan Qiu, Jingyu Yu, Xiao Hong Chen, Vishal Bhatnagar, Kirsten B Goldberg, Shenghui Tang, Paul G Kluetz, Richard Pazdur, Amna Ibrahim, Julia A Beaver, Laleh Amiri-Kordestani
FDA Approval Summary: Tivozanib for Relapsed or Refractory Renal Cell Carcinoma. Clinical cancer research : an official journal of the American Association for Cancer Research (2021)
Mirat Shah, Suparna Wedam, Joyce Cheng, Mallorie H Fiero, Huiming Xia, Fang Li, Jianghong Fan, Xinyuan Zhang, Jingyu Yu, Pengfei Song, Xiao Hong Chen, Tiffany K Ricks, Kirsten B Goldberg, Yutao Gong, William F Pierce, Shenghui Tang, Marc R Theoret, Richard Pazdur, Laleh Amiri-Kordestani, Julia A Beaver
FDA Approval Summary: Tucatinib for the Treatment of Patients with Advanced or Metastatic HER2-positive Breast Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research 27 (5) (2020)

Xiao Hong Chen.css-eqlu8i{font-size:small;padding-left:4px;} (Wei Chen)